Coya Therapeutics Receives Health Canada Approval to Expand ALS Trial to Canadian Sites
Key Insights
Health Canada has accepted Coya Therapeutics' Clinical Trial Application for COYA 302, allowing the company to initiate patient enrollment at Canadian ALS (search) centers for the ALSTARS Trial.
The ALSTARS Trial is a Phase 2, randomized, multi-center, double-blind, placebo-controlled study evaluating the efficacy and safety of COYA 302 for amyotrophic lateral sclerosis (search) treatment.
COYA 302 is an investigational biologic combination therapy comprising low-dose interleukin-2 and CTLA-4 Ig (search), designed to enhance regulatory T cell function and suppress inflammation in neurodegenerative diseases (search).
Coya Therapeutics has received regulatory clearance from Health Canada to expand its Phase 2 ALS (search) clinical trial to Canadian sites, marking a significant milestone in the company's efforts to develop novel treatments for amyotrophic lateral sclerosis (search). The Clinical Trial Application (CTA) acceptance allows for activation of clinical sites in Canada, enhancing patient recruitment alongside existing U.S. clinical sites.
The approval enables Coya to proceed with the ALSTARS Trial at Canadian ALS (search) centers, expanding the geographic reach of this pivotal study. Dr. Fred Grossman, Coya's Chief Medical Officer, emphasized the importance of this development: "The activation of Canadian sites is an important step forward for the ALSTARS Trial that we believe will further enhance recruitment of this important study currently underway in the United States. We look forward to working with the Canadian ALS centers, with the goal of potentially delivering new, safe and effective treatments for ALS."
ALSTARS Trial Design and Objectives
The ALSTARS Trial represents a Phase 2, randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of COYA 302 for ALS (search) treatment. The study is registered under ClinicalTrials.gov Identifier NCT 07161999 and includes clinical sites across both the United States and Canada.
The trial's expansion to Canadian centers is expected to accelerate patient enrollment, a critical factor in conducting robust clinical studies for rare neurodegenerative diseases (search) like ALS (search). The multi-national approach may also provide valuable insights into treatment responses across diverse patient populations.
COYA 302: Novel Immunomodulatory Approach
COYA 302 represents an investigational biologic combination therapy with a dual immunomodulatory mechanism of action. The treatment comprises proprietary low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig (search), specifically formulated for subcutaneous administration in patients with ALS (search) and other neurodegenerative diseases (search).
The therapeutic approach targets regulatory T cells (search) (Tregs (search)), aiming to enhance their anti-inflammatory function while simultaneously suppressing inflammation produced by activated monocytes (search) and macrophages (search). According to Coya, these dual mechanisms may have additive or synergistic effects in addressing the underlying pathophysiology of neurodegenerative conditions.
Regulatory T Cell Biology in Neurodegeneration
Coya Therapeutics focuses on developing treatments that leverage the biology and therapeutic potential of regulatory T cells (search) to target systemic inflammation and neuroinflammation. The company's scientific rationale centers on the understanding that dysfunctional Tregs (search) underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases.
This cellular dysfunction may lead to sustained inflammation and oxidative stress, resulting in a lack of homeostasis within the immune system. By restoring proper Treg function, COYA 302 aims to address these fundamental immunological imbalances that contribute to disease progression.
Company's Therapeutic Platform
Headquartered in Houston, Texas, Coya Therapeutics operates as a clinical-stage biotechnology company with a comprehensive approach to Treg-based therapeutics. The company's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of regulatory T cells (search).
Coya's therapeutic platforms encompass Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, representing a diversified approach to addressing immune dysfunction in various disease contexts. COYA 302 is currently an investigational product that has not yet received approval from the FDA or any other regulatory agency.